Corinne Boyer Chair in Ovarian Cancer Research
The objective of a Research Chair is to develop a strong and productive research program into a particular disease. This chair in ovarian cancer research was established 1997 in partnership with the University of Ottawa through a one million dollar gift which was matched by the university.
Named after the deceased wife of the founder of Ovarian Cancer Canada, the Corinne Boyer Chair was the first such research position in Canada. It has been held by Dr. Barbara Vanderhyden since its inception in 2001. These funds came to the organization through a grant from the Ministry of Health of Ontario in 1997.
About Dr. Barbara Vanderhyden
Dr. Vanderhyden has been conducting research on ovarian cancer since joining the Ottawa Regional Cancer Centre in 1995, focusing on communication between ovarian cells and how this communication may be disrupted, possibly preventing the development of ovarian cancers. She has also been involved as the Ottawa leader of development of the Ovarian Cancer Tissue Bank.
On June 1, 2009, Dr. Barbara Vanderhyden was the first recipient of the Rx&D Health Science Research Award at the YMCA-YWCA Women of Distinction Awards for the National Capital Region. The award recognizes enrichment to the community through excellent and significant contributions in research or the application of research in the area of health science. Dr. Vanderhyden was also honoured as a mentor and leader whose work significantly contributed to the health of the community. According to Dr. Vanderhyden, “Ovarian cancer has been a neglected topic of research. I believe that our initiative will begin to change that and to increase our ability to help women survive this devastating disease”.
“Dr. Vanderhyden has made a unique and remarkable contribution to ovarian cancer research in Canada and the advancement of women in science. She has brought together the ovarian cancer scientific and clinical communities, and has galvanized and energized the Canadian ovarian cancer landscape”, says Elisabeth Baugh, CEO of Ovarian Cancer Canada.
Gynecological Cancer Research Awards
Training and career awards to support basic, translational, clinical and health services research relevant to ovarian and other gynecological cancers were sponsored from 1999 through 2002 by a partnership involving the Mitchell Family Fund, the National Ovarian Cancer Association and Cancer Care Ontario. Because of the funding source for the grants, the awards were restricted to institutions within Ontario. Support was provided preferentially to trainees in clinical disciplines related to gynecological cancer.
The award provided salary support to the awardee up to a maximum of $75,000 per year for three years, to carry out research under the mentorship of a senior investigator with an international reputation for research excellence in areas relevant to gynecologic oncology. During this period an additional $50,000 per year was provided to support the joint research of the awardee and mentor.
Due to a change in the mandate of Cancer Care Ontario, the partnership was dissolved after the second year, however the funding commitments to the research were continued.
Fellowship in partnership with OvCaRe at BC Cancer Agency
OvCaRe stands for Ovarian Cancer Research, and OvCaRe was developed as a collaboration between the BC Cancer Agency, the Vancouver Coastal Health Research Institute, and the University of British Columbia. The goals of the initiative are threefold: to improve ovarian cancer survival through early detection of disease, to develop new therapies for ovarian cancer treatment, and to develop individualized ovarian cancer treatments. Ovarian Cancer Canada was pleased to contribute a one-time grant of $50,000 for a research fellowship for Dr. Blaise Clark.
Ovarian Cancer Research Partnership with CIHR
For more details on the recipient’s research listed below, refer to our research impact study.
2008/2009 – Dr Trevor Shepherd, University of Western Ontario. Implications of activated BMP signalling and Id1/Id3 function in ovarian cancer pathogenesis.
2008/2009 – Dr Gervais Berube, Université du Québec à Trois-Rivières. In vivo evaluation of new anticancer agents for site-specific treatment of breast and ovarian cancers.
2010/2011 - Dr. Jim Petrik, University of Guelph Ontario Veterinary College and McMaster University Department of Obstetrics and Gynecology. Use of Thrombospondin-1 (TSP-1) to destroy abnormal and immature tumour blood vessels while leaving healthy blood vessels unchanged. Dr. Petrik plans to complete the studies with mice using an extended timeframe and combination therapy. He then hopes to progress to clinical trials to assess the safety and potential benefits of the TSP-1 and low-dose chemotherapy approach in women with advanced ovarian cancer.
2010/2011 - Dr. Barbara Vanderhyden of the Ottawa Hospital Research Institute. Role of Sca1+ ovarian surface epithelial cells in ovulatory wound repair.
2011/2012 - Dr. Catherine Classen, Women’s College Hospital, Toronto. A randomized controlled trial of an online support group for sexual distress due to gynecologic cancer.
2011/2012 - Dr. Joanne Kotsopoulos, Women’s College Hospital, Toronto - Telomere Length and Ovarian Cancer Prognosis. This study will evaluate whether telomere length is related to various clinical or pathological features of an ovarian tumor.
Pilot Project Research on Early Detection and Prevention of Ovarian Cancer
OCC regards early detection of ovarian cancer as one of the highest priorities as it can have the most significant impact on the outcomes for ovarian cancer patients. In 2008 and 2009 OCC funded pilot projects addressing the early detection and/or prevention of ovarian.
2008 – Dr Michelle Letarte, The Hospital for Sick Children. Proteins differentially expressed in ovarian epithelium of BRCA1 carriers as potential biomarkers for ovarian cancer
2008 –Dr Steven Narod, Women’s College Hospital. Prevention of Hereditary Ovarian Cancer with Oral DIM Supplementation
2008 - Dr. Eleftherios Diamandis, Mount Sinai Hospital. Discovery of a Novel Candidate Biomarker for Early Ovarian Cancer Detection.
2008 - Jessica McAlpine, University of British Columbia and BC Cancer Agency. - Ovarian Cancer Early Screening Project (OCESP) in BC.
2008 – Patricia Shaw. Biomarkers in High Grade Adnexal Serous Carcinoma.
2008 – David Malkin. Telomere Length and Age of Onset in Hereditary Ovarian Cancer
2009 –Dimcho Bachvarov, Laval University. MicroRNAs (miRNAs) could be novel, clinically useful and non-invasive biomarkers for blood-based early detection of epithelial ovarian cancer.
2009 - Dr. Patricia Tonin, The Research Institute of the McGill University Health Centre & McGill University - Genomic anomalies in serous borderline and benign ovarian tumours.
2009 - Eva Turley, London Regional Cancer Program, The University of Western Ontario - A wound healing-like response during ovarian tumour growth may help develop a biomarker screening strategy for early detection.
2009 - Dr. Barbara Vanderhyden, University of Ottawa/Ottawa Health Research Institute - Characterization of stem/progenitor cells in the ovarian surface epithelium.
2009 - Dr. Yuzhuo Wang, BC Cancer Research Agency - MicroRNAs sensitivity and specificity for effective detection of high grade serous carcinoma.
Ovarian Cancer Consensus Conference
The Gynecologic Cancer Intergroup (GCIG) focuses on the development of new methodologies, endpoints, and designs for the conduct of clinical trials in those women affected by ovarian cancer. Since 1997, the GCIG has had in excess of 40 publications related to trial outcomes, methodology, quality of life indexes, and translational research.
This international collaboration has allowed the conduct of clinical trials in a manner that cannot be accomplished by any one individual cooperative group and allows rapid accrual and identification of outcomes.
Every few years, the GCIG has convened a consensus conference to develop a series of statements on behalf of the GCIG to guide the planning of future clinical trials in this domain. The results of these consensus conferences have been published and have been utilized worldwide as guidelines and parameters for such trials. Indeed, such agencies as the FDA in the US have utilized these guidelines in understanding other clinical trials in different diseases and disease sites.
In Spring 2010, Ovarian Cancer Canada was a sponsor of this international event taking place at the University of British of Columbia.
This award was provided to a student in 1998 as part of an initiative with the Genesis Research Foundation.